The Pennant Group (PNTG) Fundamentals 2026 — P/E 45.4x, Revenue Analysis | SniperIQ
The Pennant Group (PNTG) is a US-listed Healthcare company in Medical - Care Facilities with a market capitalization of
.4B, trading at $40.40 on the NASDAQ. This SniperIQ fundamentals page covers The Pennant Group's valuation (P/E 45.4x, P/B 4.1x), profitability (net margin 3.0%), revenue ($948M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market Cap
.4B
P/E (TTM)45.4x
Net Margin3.0%
Revenue (FY25)$948M
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is The Pennant Group's market cap?
The Pennant Group (PNTG) has a market capitalization of approximately
.4B, trading at $40.40 on the NASDAQ. Market cap moves with the live share price.
What is The Pennant Group's P/E ratio?
The Pennant Group's trailing twelve-month P/E ratio is 45.4x, with a price-to-book (P/B) of 4.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is The Pennant Group?
The Pennant Group runs a net profit margin of 3.0%, a gross margin of 14.8%, and an operating margin of 5.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does The Pennant Group generate?
The Pennant Group reported revenue of $948M for fiscal year 2025, with net income of
0M and earnings per share (EPS) of 0.86. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does The Pennant Group pay a dividend?
The Pennant Group does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is The Pennant Group financially healthy?
The Pennant Group carries a debt-to-equity ratio of 1.31x and a current ratio of 1.19x, with a market beta of 1.25. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is The Pennant Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For The Pennant Group (PNTG) the key facts are: market cap
.4B, P/E 45.4x, revenue $948M, 52-week range 21.73-42.55. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track The Pennant Group's full fundamentals live
Get The Pennant Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.